Finding markers that indicate protection or risk from dengue vaccines and infections
Identification of serological markers of protection and risk for dengue vaccines and natural infection
This study is looking at how our immune system reacts to dengue, whether from getting the virus or from vaccines, to find out what signs can show if someone might get severe dengue or be safe from it, and it involves checking blood samples from people over several years to see how these immune responses change.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11159254 on NIH RePORTER |
What this research studies
This research investigates how the immune response to dengue, both from natural infections and vaccinations, can be better understood. It focuses on identifying specific markers that indicate whether a person is at risk for severe dengue or is protected against it. By analyzing blood samples from individuals over several years, the study aims to characterize both neutralizing and non-neutralizing antibody responses, as well as cellular immune responses. This comprehensive approach will help clarify how these immune responses change over time and their relationship to disease risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been vaccinated against dengue or have experienced dengue infections.
Not a fit: Patients who have never been exposed to dengue or have not received any dengue vaccinations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved dengue vaccines and better strategies for managing dengue infections.
How similar studies have performed: Previous research has shown promise in understanding immune responses to dengue, but this study aims to provide deeper insights into both neutralizing and non-neutralizing responses, making it a novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Cummings, Derek a — Johns Hopkins University
- Study coordinator: Cummings, Derek a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.